Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists01:29

Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists

1.1K
Dopamine receptor antagonists, also known as antipsychotic agents, are critical in managing chemotherapy-induced vomiting. These antiemetic agents block dopamine receptors in the chemoreceptor trigger zone (CTZ), inhibiting signal transmission to the vomiting center. Antipsychotic agents encompass phenothiazines (PTZ), butyrophenones, benzamides, and thienobenzodiazepines (Zyprexa), which are utilized for their antiemetic and sedative properties.
Phenothiazines, such as prochlorperazine...
1.1K
Chemotherapy-Induced Nausea and Vomiting: Cannabinoids01:21

Chemotherapy-Induced Nausea and Vomiting: Cannabinoids

935
Tetrahydrocannabinol (THC) is a phytocannabinoid that primarily interacts with the CB1 receptor, a type of G protein-coupled receptor (GPCR) predominantly in and around the chemoreceptor trigger zone (CTZ) and emetic center. THC also blocks the serotonin receptor activity in the dorsal vagal complex (DVC) by inhibiting serotonin release. THC exerts its anti-emetic effects through these interactions, which are beneficial for patients undergoing chemotherapy.
Two synthetic agonists of THC,...
935
Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists01:27

Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists

824
5-HT3 receptor antagonists, such as dolasetron, granisetron (Kytril), ondansetron (Zofran), and palonosetron (Axoli), are crucial in managing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea. These drugs selectively block 5-HT3 receptors in the visceral vagal and spinal afferent nerves, chemoreceptor trigger zone, and the vomiting center. They have a rapid onset of action and can be given as a single dose before chemotherapy. Ondansetron and granisetron, in particular,...
824
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists01:28

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists

752
Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy.  SP binds and activates...
752
Nursing Ethical Principles II01:27

Nursing Ethical Principles II

2.6K
Ethical principles are essential in guiding nurses to fulfill their responsibilities, focusing on the quality of nursing care and decision-making. These principles, including autonomy, beneficence, non-maleficence, justice, and fidelity, shape the ethical framework within healthcare settings.
Consider the following scenario, which illustrates how these principles are applied in the care of Mr. John, a fifty-year-old teacher diagnosed with metastatic liver cancer.
Initially, Mr. John's...
2.6K
Drug toxicity: Drug–Drug Interaction01:30

Drug toxicity: Drug–Drug Interaction

337
Drug–drug interactions can precipitate toxicity through multiple mechanisms. Absorption interactions alter how drugs enter the body, exemplified when ranitidine increases the absorption of basic drugs, while cholestyramine decreases the levels of propranolol. Protein binding interactions occur when drugs share the same binding sites on plasma proteins. Drugs like aspirin and warfarin, when bound in excess, can lead to increased free drug concentrations, enhancing the potential for...
337

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

An Autoimmune Haemolytic Anaemia Secondary to Ipilimumab Treatment.

Klinicka onkologie : casopis Ceske a Slovenske onkologicke spolecnosti·2017
Same author

Sentinel Lymph Node in Melanoma -  a Study Conducted in the South of Brazil.

Klinicka onkologie : casopis Ceske a Slovenske onkologicke spolecnosti·2016
Same author

A rare neoplastic growth on the ear lobe.

Klinicka onkologie : casopis Ceske a Slovenske onkologicke spolecnosti·2014
Same author

Analysis of disease-free survival and overall survival in patients with luminal a breast cancer stratified according to TNM.

Klinicka onkologie : casopis Ceske a Slovenske onkologicke spolecnosti·2014
Same author

Bevacizumab as secondline treatment of glioblastoma -  worth the effort?

Klinicka onkologie : casopis Ceske a Slovenske onkologicke spolecnosti·2014
Same author

Wage -specific assessment of mammography screening in Brazilian women.

Klinicka onkologie : casopis Ceske a Slovenske onkologicke spolecnosti·2014

Related Experiment Video

Updated: Mar 31, 2026

Chemotherapy-induced Vascular Toxicity - Real-time In vivo Imaging of Vessel Impairment
04:48

Chemotherapy-induced Vascular Toxicity - Real-time In vivo Imaging of Vessel Impairment

Published on: January 7, 2015

7.8K

Forbidden to Drive -  a New Chemotherapy Side Effect.

R K Rovere, A Silva De Lima

    Klinicka Onkologie : Casopis Ceske a Slovenske Onkologicke Spolecnosti
    |October 21, 2015
    PubMed
    Summary

    Capecitabine, an oral cancer drug, can cause severe hand-foot syndrome, leading to temporary fingerprint loss. This rare side effect requires physician recognition as a treatment-related issue.

    Area of Science:

    • Oncology
    • Pharmacology

    Background:

    • Capecitabine is an oral pyrimidine analogue antineoplastic agent used in various cancers.
    • Common adverse effects include diarrhea and hand-foot syndrome.
    • Rarely, extreme cases can lead to loss of fingerprints.

    Observation:

    • A 47-year-old male with metastatic rectal cancer received capecitabine treatment.
    • The patient developed severe hand-foot syndrome as a side effect.
    • This syndrome resulted in the complete loss of his fingerprints.

    Findings:

    • The patient's severe hand-foot syndrome resolved completely after discontinuing capecitabine.
    • Fingerprint loss, a rare consequence of capecitabine-induced hand-foot syndrome, was observed.
    • The condition highlights a treatment-related side effect impacting patient quality of life.

    More Related Videos

    Nerve Excitability Assessment in Chemotherapy-induced Neurotoxicity
    07:42

    Nerve Excitability Assessment in Chemotherapy-induced Neurotoxicity

    Published on: April 26, 2012

    18.7K
    Acupoint Application Combined with Acupressure as an Adjunctive Therapy for Chemotherapy-Induced Nausea and Vomiting
    05:56

    Acupoint Application Combined with Acupressure as an Adjunctive Therapy for Chemotherapy-Induced Nausea and Vomiting

    Published on: June 21, 2024

    2.5K

    Related Experiment Videos

    Last Updated: Mar 31, 2026

    Chemotherapy-induced Vascular Toxicity - Real-time In vivo Imaging of Vessel Impairment
    04:48

    Chemotherapy-induced Vascular Toxicity - Real-time In vivo Imaging of Vessel Impairment

    Published on: January 7, 2015

    7.8K
    Nerve Excitability Assessment in Chemotherapy-induced Neurotoxicity
    07:42

    Nerve Excitability Assessment in Chemotherapy-induced Neurotoxicity

    Published on: April 26, 2012

    18.7K
    Acupoint Application Combined with Acupressure as an Adjunctive Therapy for Chemotherapy-Induced Nausea and Vomiting
    05:56

    Acupoint Application Combined with Acupressure as an Adjunctive Therapy for Chemotherapy-Induced Nausea and Vomiting

    Published on: June 21, 2024

    2.5K

    Implications:

    • Physicians must recognize fingerprint loss as a potential, albeit rare, side effect of capecitabine therapy.
    • This rare condition, though not a disease itself, can significantly affect a patient's quality of life.
    • Awareness of such side effects is crucial for comprehensive patient care in oncology.